Skip to main content

Does a Gout Flare Increase Risk of a Cardiovascular Event?

ejdein@gmail.com
Nov 16, 2026 7:45 am

Gout is a metabolic and inflammatory disorder associated with increased cardiovascular risk and premature mortality, although causality has been uncertain. In 2022, Cipolletta and colleagues published a study in JAMA that demonstrated a temporal association between gout flares and subsequent major adverse cardiovascular events (MACE). This study reported 93% higher odds of MACE in the 60 days after a gout flare (odds ratio 1.93, 95% confidence interval 1.57-2.38) and 57% higher odds between 61-120 days after a gout flare (OR 1.57; 1.26-1.96). This study prompted many rheumatologists to consider acute gout flares a potential short-term cardiovascular risk factor.

Initiation of urate-lowering therapy (ULT) can paradoxically precipitate gout flares, particularly in the initial months of treatment. Do these ULT-associated flares also increase cardiovascular risk? Dr. Chio Yokose and colleagues addressed this question in abstract #1820, presented during the plenary session at the 2026 ACR Convergence.

The investigators conducted a post-hoc analysis of the 2019 CARES trial, originally designed to compare the cardiovascular safety of febuxostat and allopurinol in 6,190 patients with gout and established cardiovascular disease (CVD). One important distinction between these studies is the identification of gout flare. The Cipolletta trial retrospectively relied upon billing codes for gout along with prescribed flare medications (colchicine, NSAID, or glucocorticoid). In contrast, the CARES study prospectively collected detailed information regarding gout flares, timing, clinical features, and physician adjudication. The investigators used the Gaffo definition, which requires at least 3 of 4 criteria (patient-defined flare, pain at rest >3 out of 10, at least one swollen joint, at least one warm joint). Using a nested case-control study, the authors were able to examine the relationship between recent gout flares and subsequent MACE within CARES trial.

This post-hoc analysis, showed no association between MACE and recent gout flare events. When using the Gaffo-confirmed flares definition, there was no association either within the 60 day window (OR 0.98; 0.67-1.44) or the 61-120 day window (OR 1.11; 0.72-1.71). The authors performed many sensitivity analyses including physician-adjudicated flares, flares with swelling, flares with warmth, and flares with tenderness, but none demonstrated any correlation between gout flare and MACE.

In conclusion, this analysis of the CARES study does not find an association between gout flares occurring after initiation of urate-lower therapy and MACE risk. How can we square these results with the seeming contradiction from the prior literature? This study provides high-quality prospective data with adjudicated data, granularity on patient flares, and robust sensitivity analyses that corroborate the primary finding. One potential explanation is that the Cipolletta trial design influenced their results, as their definition of gout flare was reliant upon pharmacologic treatments including NSAIDs and corticosteroids, two therapies with known cardiovascular risk. This study may have captured the effect of these therapies, rather than the gout flare itself.

This trial demonstrates to me that there is safety in starting urate-lower therapy in gout patients, even if there is increased risk of gout flares upon initiation. There is a clear link demonstrated in the literature that gout history is correlated with cardiovascular risk, and it can be considered part of metabolic syndrome. That said, the transient inflammatory disease of acute gout flares may not be the full culprit, and risks associated with abortive therapy are important to consider. Further prospective studies will be needed to distinguish the effects of gout-related inflammation from those of treatment. In the meantime, however, we should continue to prioritize appropriate ULT initiation, treat-to target urate management, and cardiovascular risk reduction in our patients with gout.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×